Cyclacel Pharmaceuticals Inc.
Find Ratings ReportsCYCLACEL PHARMACEUTICALS's gross profit margin for the third quarter of its fiscal year 2023 has significantly decreased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the subsector when comparing net income growth, but not when comparing revenue growth.
At the same time, stockholders' equity ("net worth") has significantly decreased by 83.82% from the same quarter last year.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q3 FY23 | Q3 FY22 |
---|---|---|
Net Sales ($mil) | 0.02 | 0.0 |
EBITDA ($mil) | -6.84 | -6.46 |
EBIT ($mil) | -6.85 | -6.47 |
Net Income ($mil) | -6.03 | -5.1 |
Balance Sheet | Q3 FY23 | Q3 FY22 |
---|---|---|
Cash & Equiv. ($mil) | 5.94 | 23.71 |
Total Assets ($mil) | 12.5 | 31.02 |
Total Debt ($mil) | 0.05 | 0.11 |
Equity ($mil) | 4.3 | 26.56 |
Profitability | Q3 FY23 | Q3 FY22 |
---|---|---|
Gross Profit Margin | -42737.5 | 0.0 |
EBITDA Margin | -42737.5 | 0.0 |
Operating Margin | -42781.25 | 0.0 |
Sales Turnover | 0.03 | 0.0 |
Return on Assets | -197.67 | -61.48 |
Return on Equity | -541.47 | -69.21 |
Debt | Q3 FY23 | Q3 FY22 |
---|---|---|
Current Ratio | 1.36 | 6.41 |
Debt/Capital | 0.01 | 0.0 |
Interest Expense | 0.0 | 0.0 |
Interest Coverage | 0.0 | 0.0 |
Share Data | Q3 FY23 | Q3 FY22 |
---|---|---|
Shares outstanding (mil) | 0.84 | 0.84 |
Div / share | 0.0 | 0.0 |
EPS | -7.2 | -6.45 |
Book value / share | 5.1 | 31.77 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 179303.0 | 186054.0 |
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 0.49 indicates a significant discount versus the S&P 500 average of 4.68 and a significant discount versus the subsector average of 19.07. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average. After reviewing these and other key valuation criteria, CYCLACEL PHARMACEUTICALS proves to trade at a discount to investment alternatives.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CYCC NM | Peers 85.83 | CYCC NM | Peers 38.76 | |||||||||||||||||||||
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. CYCC's P/E is negative making this valuation measure meaningless. |
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. CYCC's P/CF is negative making the measure meaningless. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
CYCC NM | Peers 18.08 | CYCC NA | Peers 1.16 | |||||||||||||||||||||
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings. CYCC's ratio is negative making this valuation measure meaningless. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
CYCC 0.49 | Peers 19.07 | CYCC -8.64 | Peers 12.58 | |||||||||||||||||||||
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. CYCC is trading at a significant discount to its peers. |
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. However, CYCC is expected to significantly trail its peers on the basis of its earnings growth rate. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
CYCC 5.40 | Peers 84.44 | CYCC NA | Peers 42.35 | |||||||||||||||||||||
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. CYCC is trading at a significant discount to its subsector on this measurement. |
Neutral. Comparing a company's sales growth to its subsector helps to determine if the company is adding or losing market share. The growth rate for CYCC is not available. |
|||||||||||||||||||||||